A股異動 | 利好疊加 新華醫療(600587.SH)漲近7%
格隆匯12月31日丨新華醫療(600587.SH)股價震盪拉昇,現報32.48元,創近四個月新高,漲幅6.8%,總市值132億。公司公吿稱,擬定增募資不超12.84億元,用於高端精密微創手術器械生產擴建項目等。此外,公司還將收購德國蛇牌公司所持的新華手術器械40%股權。光大證券指,公司作為感控設備和製藥裝備龍頭,產品體系健全,具備一體化解決方案能力,有望充分享受醫療新基建和製藥裝備行業高速發展紅利,維持對公司“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.